The 10-second takeaway
For the quarter ended June 30 (Q2), Bristol-Myers Squibb met expectations on revenues and earnings per share.
Compared to the prior-year quarter, revenue contracted significantly and GAAP earnings per share dropped significantly.
Margins shrank across the board.
Bristol-Myers Squibb notched revenue of $4.44 billion. The 13 analysts polled by S&P Capital IQ predicted a top line of $4.43 billion on the same basis. GAAP reported sales were 18% lower than the prior-year quarter's $5.43 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.48. The 16 earnings estimates compiled by S&P Capital IQ forecast $0.48 per share. GAAP EPS of $0.38 for Q2 were 27% lower than the prior-year quarter's $0.52 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 72.0%, 110 basis points worse than the prior-year quarter. Operating margin was 23.1%, 1,030 basis points worse than the prior-year quarter. Net margin was 14.2%, 240 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $3.96 billion. On the bottom line, the average EPS estimate is $0.40.
Next year's average estimate for revenue is $17.88 billion. The average EPS estimate is $1.93.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,660 members out of 1,774 rating the stock outperform, and 114 members rating it underperform. Among 462 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 444 give Bristol-Myers Squibb a green thumbs-up, and 18 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bristol-Myers Squibb is outperform, with an average price target of $34.85.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Bristol-Myers Squibb. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Bristol-Myers Squibb to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.